Lausanne University Hospital
Lausanne, Vaud Canton, 1011, Switzerland
NCT Number: NCT07157540
The goal of this clinical trial is to learn if a digital web application can prevent the risks related to cannabis use among adult regular cannabis users who are enrolled in a pilot trial for cannabis sales regulation conducted in Lausanne, Switzerland (i.e., Cann-L study) and have agreed that their data were used in other studies.
The main question it aims to answer is:
Do participants who have access to the intervention modules of the web application raise their use of protective behavioral strategies to lower cannabis-related risks?
Researchers will compare the intervention modules to a control module (i.e., information on cannabis-related risks and harm reduction) to see if the web application works to prevent the risks related to cannabis use. They will also compare intervention modules across each other to see whether one works better than another.
Participants will:
* Create a user account in the web application * Access the web application using a laptop, tablet or smartphone * Use the web application as they wish throughout the duration of the study * Complete the regular Cann-L study questionnaires every six months, which will be used to measure their cannabis use and related risks.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Lausanne, Vaud Canton, 1011, Switzerland
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Inclusion criteria
in Cann-L study are:
Exclusion criteria
The consent to participate in the Cann-L parent trial comprises an option to be contacted to participate in sub-studies, including studies on prevention measures. All participants having accepted to be so contacted will be proposed to participate in the present study.
Therefore, additional exclusion criteria for the present study include:
PF comprises the following content:
Two-task intervention including:
SFAS includes:
Minimal intervention (Control Intervention), consisting of simple, text-only web pages containing information on cannabis effects and health-related risks, cannabis consumption modes, cannabis harm reduction and protective behavioral strategies, as well as hyperlinks to additional resources and online help.
Time frame: This outcome will be assessed at 1- and 7-month follow-up.
This outcome will be measured using the Protective Behavioral Strategies for Marijuana Use (PBSM-17) Short Form scale, a self-reported 17-item questionnaire measuring the frequency of PBS for cannabis use on a 6-point Likert scale ranging from 1 (never) to 6 (always).
Time frame: This outcome will be measured at 1- and 7-month follow-up.
Cannabis Use Frequency will be measured using a single item asking "During the past 30 days, on how many days did you use cannabis?"
Time frame: This outcome will be measured at 1- and 7-month follow-up.
The number of hours under influence will be measured using a single item asking "How many total hours were you high on a typical day when you had been using cannabis?"
Time frame: This outcome will be measured at 1- and 7-month follow-up.
This outcome will be measured using the Cannabis Use Disorder Identification Test - Revised (CUDIT-R), a self-reported 8-items questionnaire (i.e., question 1-7 are scored on a 0-4 scale, and question 8 is scored 0, 2, or 4). Scores of 8 or more indicate hazardous cannabis use, while scores of 12 or more indicate a possible cannabis use disorder for which further intervention may be required.
Time frame: This outcome will be assessed at 1- and 7-month follow-up.
This outcome will be used to measure behavioral economics indices of cannabis demand. Participants will be asked to report hypothetical cannabis consumption in a scenario at escalating prices.
Time frame: This outcome will be assessed at 1- and 7-month follow-up.
This outcome will be measured for each cannabis product (herbal/marijuana, resin/hashish, oral oil, e-liquids, concentrates, edibles, other) by reporting the frequency of supply in a) Cann-L study dispensary, b) other external sources (e.g., acquaintances, on the street, social networks, darknet).
Time frame: This outcome will be assessed at 1- and 7-month follow-up.
The frequency of use of four main consumption modes (smoking, vaping/dabbing, absorbing, and edibles) will be measured using four corresponding cursors for which the total should be 100%.
Time frame: This outcome will be assessed at 1- and 7-month follow-up.
This outcome will be computed based on individual sales data from Cann-L study dispensary.
Time frame: This outcome will be assessed at 1- and 7-month follow-up.
This outcome will be assessed by two items measuring the frequency of simultaneous use, one for alcohol and one for other illegal drugs.
Jacques Gaume
Other
Testing the Effects of a Digital Intervention for Cannabis Harm Reduction - The Cann'App Fractional Factorial Randomized Controlled Trial
Acronym: Cann'App
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07725289
Adolescent Substance Use, Behavior
Boston, Massachusetts, United States
View Trial DetailsNCT07513337
Cannabis Use
Baltimore, Maryland, United States
View Trial DetailsNCT07496489
Cannabis Use, Chemically-Induced Disorders
Winston-Salem, North Carolina, United States
View Trial DetailsNCT04812613
Behavior, Cannabis Use
Ottawa, Ontario, Canada
View Trial Details